EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 359 filers reported holding EXELIXIS INC in Q1 2023. The put-call ratio across all filers is 0.23 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $33,443 | -1.5% | 1,750 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $33,968 | +21.0% | 1,750 | 0.0% | 0.00% | +33.3% |
| Q4 2022 | $28,070 | +4.0% | 1,750 | 0.0% | 0.00% | -25.0% |
| Q3 2022 | $27,000 | -25.0% | 1,750 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $36,000 | -10.0% | 1,750 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $40,000 | +25.0% | 1,750 | 0.0% | 0.00% | +33.3% |
| Q4 2021 | $32,000 | -13.5% | 1,750 | 0.0% | 0.00% | -25.0% |
| Q3 2021 | $37,000 | +15.6% | 1,750 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $32,000 | -20.0% | 1,750 | 0.0% | 0.00% | -20.0% |
| Q1 2021 | $40,000 | +14.3% | 1,750 | 0.0% | 0.01% | 0.0% |
| Q4 2020 | $35,000 | -18.6% | 1,750 | 0.0% | 0.01% | -28.6% |
| Q3 2020 | $43,000 | +2.4% | 1,750 | 0.0% | 0.01% | 0.0% |
| Q2 2020 | $42,000 | +40.0% | 1,750 | 0.0% | 0.01% | +16.7% |
| Q1 2020 | $30,000 | +1400.0% | 1,750 | +1650.0% | 0.01% | +500.0% |
| Q1 2018 | $2,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |